{"database":"ecrin-mdr-crc","file_versions":[],"scores":null,"additional":{"omics_type":["Clinical"],"study_start_year":["2010"],"condition":["CRC","Colorectal cancer","Colonic Neoplasms","Cancer"],"disease":["Crc","Colorectal Cancer","Colonic Neoplasms","Cancer"],"study_type":["Interventional"],"full_dataset_link":["https://newmdr.ecrin.org/Study/2103210"],"location":["Greece"],"study_start_month":["10"],"keyword":["Adjuvant chemotherapy","Oxaliplatin","Capecitabine","Levoleucovorin","Leucovorin","5 fluorouracil","Fluorouracil"],"repository":["ECRIN MDR"],"study_status":["Not provided"],"additional_accession":[]},"is_claimable":false,"name":"Adjuvant Therapy(3 vs. 6 Months) With the FOLFOX 4 or XELOX for Stage II or Stage III Colon Cancer","description":"The purpose of this study is to compare whether a 3-month treatment is at least not inferior to a 6-month treatment (FOLFOX-4 6 vs. 12 cycles or XELOX 4 cycles vs. 8 cycles) in terms of RFS in patients with high risk stage II or stage III radically resected colon cancer.","dates":{"creation":"2010-10-15"},"accession":"2103210","cross_references":{"ClinicalTrials___gov":["NCT01308086"]}}